CDMO and biotech Forge Biologics will be acquired by Ajinomoto in an all-cash deal worth $620 million, a move that will see the Japan-based multinational conglomerate enter the gene therapy manufacturing space.
“Clearly, Ajinomoto is seeing this as a bet on the future of gene therapy, and that this will become a more important part of CDMO offerings into the future,” Forge board chair Chris Garabedian told Endpoints News in an interview.
The $620 million represents Forge’s enterprise value on a cash-free and debt-free basis. But by the time the purchase is closed, its equity value is estimated to be $554 million, according to a press release.
The deal, which is anticipated to close before the end of the year, would make Forge a fully consolidated subsidiary of Ajinomoto. Forge is headquartered in a 200,000-square-foot cGMP site in Columbus, OH, and employs more than 300 workers.
Forge had many interactions with both investors and possible strategic partners in the past year, Garabedian said. “[And] these processes often evolve and, until you have a company that has the right price, that makes sense — for the Forge management team, the board of directors, the investors — that’s when these deals get consummated,” he noted.
The deal is designed to boost Ajinomoto’s CDMO services, particularly in AAV and plasmid gene therapy manufacturing. Ajinomoto, known for its food seasoning products, also has a CDMO business that provides GMP manufacturing and aseptic fill-finish services for small and large molecules.
A Forge spokesperson said in an email to Endpoints that both companies are “committed to retaining Forge’s talent and ensuring a smooth transition.”
“The management team was a big part of the reason for the acquisition — Ajinomoto really was impressed with Forge’s ability to execute in this space,” Garabedian added. “In terms of all the interactions, the expectation is they [Ajinomoto] want to make sure that they can retain the staff and may even have plans for growth, but that’s up to Ajinomoto post-closing.”
On top of its CDMO services, Forge has two assets under investigation: Phase I/II FBX-101 in Krabbe disease and preclinical candidate FBX-201 for rare monogenic diseases. Since Forge is being wholly acquired, it will advance its clinical pipeline, the spokesperson said. Forge last reported positive data for FBX-101 in February.
“In this current market environment, there’s a lot of concerns about headwinds for our industry. This is at least a signal from a well-regarded CDMO and services firm [Ajinomoto] that they really are betting on growth. And this sector, particularly in gene therapy, will continue to thrive,” Garabedian added.
Forge’s last fundraise was a Series C worth $90 million in September last year. Before that, it closed a $120 million Series B in April 2021 and a $40 million Series A in July 2020.
Check out our AAV CDMO service to expedite your gene therapy research
https://endpts.com/ajinomoto-to-buy-gene-therapy-cdmo-forge-biologics-in-620m-all-cash-deal/
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Related News
Another Two-Plasmid AAV Gene Therapy Enters Clinical Trial: Gene Vector Biotechnology’s JWK001 Pioneers in Treating nAMD
On November 30, 2023, Gene Vector Biotechnology Co., Ltd. in Chengdu, China, received approval from the National Medical Products Administration's Center for Drug Evaluation (CDE) for the clinical trial of JWK001, a Class I gene therapy drug for treating neovascular...
Accelerating Gene Therapy Production: Combining next-generation AAV vectors and artificial intelligence (AI)
Recently, the France-based WIDGeT consortium emerged from a collaboration between Sanofi, WhiteLab Genomics, the TaRGeT Laboratory at Nantes University, and Institut Imagine. Scientists and companies in this consortium hope to speed up the development of gene...
REGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal dose determination and initiation of pivotal program in 2024...
FDA is investigating whether CAR-T, a cancer therapy pioneered at Penn, can cause lymphoma
Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug...
